Global Hunter Securities Starts Furiex Pharmaceuticals (FURX) at Buy; Diverse Pipeline Opens Multiple Opportunities
Tweet
Share
E-mailGet Alerts FURX Hot Sheet
Price: $104.77 --0%
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Global Hunter Securities initiates coverage on Furiex Pharmaceuticals (NASDAQ: FURX) with a Buy. PT $18.00.
Global analyst says, "The company’s business model is to enter into licensing agreements with larger partners following completion of clinical proof of concept studies. FURX's most advanced partnered program is Nesina, a DPP-4 inhibitor for type 2 diabetes, licensed to Takeda. Nesina is approved in Japan and has a 1Q12 PDUFA date in the U.S. Other pipeline drugs include a small molecule modulator of the mu and delta opioid receptors called MuDelta, for irritable bowel syndrome with diarrhea (IBS-d); a novel statin, PPD-10558, for dyslipidemia patients who experience statin-associated myalgia; and JNJ-Q2, a novel fluoroquinolone antibiotic, for community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Finally, the company receives royalties on worldwide sales of J&J's (NYSE: JNJ) Priligy, for premature ejaculation. Priligy is approved in Europe and certain Asian and Latin American countries. We believe the depth of FURX’s pipeline and the company’s prior experience as a contractor for the pharmaceutical industry combine to create a promising long-term story."
For more ratings news on Furiex Pharmaceuticals click here and for the rating history of Furiex Pharmaceuticals click here.
Shares of Furiex Pharmaceuticals closed at $13.53 yesterday.
Global analyst says, "The company’s business model is to enter into licensing agreements with larger partners following completion of clinical proof of concept studies. FURX's most advanced partnered program is Nesina, a DPP-4 inhibitor for type 2 diabetes, licensed to Takeda. Nesina is approved in Japan and has a 1Q12 PDUFA date in the U.S. Other pipeline drugs include a small molecule modulator of the mu and delta opioid receptors called MuDelta, for irritable bowel syndrome with diarrhea (IBS-d); a novel statin, PPD-10558, for dyslipidemia patients who experience statin-associated myalgia; and JNJ-Q2, a novel fluoroquinolone antibiotic, for community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Finally, the company receives royalties on worldwide sales of J&J's (NYSE: JNJ) Priligy, for premature ejaculation. Priligy is approved in Europe and certain Asian and Latin American countries. We believe the depth of FURX’s pipeline and the company’s prior experience as a contractor for the pharmaceutical industry combine to create a promising long-term story."
For more ratings news on Furiex Pharmaceuticals click here and for the rating history of Furiex Pharmaceuticals click here.
Shares of Furiex Pharmaceuticals closed at $13.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BMO Capital Starts Energy Fuels (UUUU) at Outperform
- Leerink Starts Ligand Pharma (LGND) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
